Research Topic: posaconazole

Fungal Pneumonia and Severe Neutropenia: Risk Factors for Increased 90 Day Mortality

mycolabadmin

This study examined 39 cancer patients with severe fungal lung infections treated at a major cancer center. Patients who received antifungal treatment within 7 days and started with a specific drug called liposomal amphotericin B had better survival rates at 90 days. The research suggests that quick diagnosis and prompt treatment initiation are critical for improving survival in immunocompromised patients with fungal pneumonia.

Read More »

Breakthrough Invasive Mould Infections Under Posaconazole Prophylaxis in Patients With Haematologic Malignancies: A Case–Control Study

mycolabadmin

This study examined cases where patients receiving posaconazole to prevent fungal infections still developed serious mould infections despite the medication. Researchers compared 29 patients who developed these breakthrough infections with 46 control patients who did not. They found that over half of patients with breakthrough infections died, compared to only 20% of controls, and that surgical treatment significantly improved survival for certain types of fungal infections.

Read More »
Scroll to Top